Splenomegaly refers to an abnormal enlargement of the spleen. In the context of oncology and hematology pharmacy, it is a clinical marker used for diagnosis, risk stratification, and monitoring treatment response.
Clinical Context
- Disease Presentation: Splenomegaly is a classic presenting symptom for Chronic Myeloid Leukemia (CML), often accompanied by a very high white blood cell count [Conversation History].
- Lineage Distinction: While leukemia typically begins in the bone marrow and travels through the bloodstream, lymphomas are cancers of the lymphatic system that can originate in the lymph nodes or the spleen.
- Differential Diagnosis: Oncology pharmacists and clinicians must distinguish splenomegaly from hepatomegaly (enlarged liver). While both can occur in advanced malignancies, painful hepatomegaly—accompanied by weight gain and jaundice—is a specific hallmark of Sinusoidal Obstruction Syndrome (SOS), a severe toxicity associated with agents like gemtuzumab ozogamicin.